[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-513619-105":59,"doc-detail-513619-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","covid-19-and-clinical-trials-the-medidata-perspective-release-30","COVID 19 AND CLINICAL TRIALS - THE MEDIDATA PERSPECTIVE - Release 3.0","","COVID-19 has materially disrupted clinical trials worldwide, with Medidata reporting sharp declines in new patient enrollment in actively recruiting studies and continuing growth in the pandemic’s enrollment impact across most countries. The report quantifies year-over-year decreases in new patients per study-site and introduces a new metric tracking visits per study subject, showing reduced visits through early 2020. It also summarizes emergency regulatory guidance across major authorities, highlighting country-by-country differences and evolving practices for protocol amendments, risk assessment, consent, and remote monitoring.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/covid-19-and-clinical-trials-the-medidata-perspective-release-30/513619/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/covid-19-and-clinical-trials-the-medidata-perspective-release-30/513619.png","ImageObject",300,407,{"name":92,"@type":93},"Mary Man","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-10-06",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How did COVID-19 affect new patient enrollment in clinical trials, according to the report?","Question",{"text":113,"@type":114},"Medidata analysis shows a 75% decrease in the average number of new patients entering trials per study-site for the first two weeks of April (YoY), compared with the same period last year. The impact continued to grow in most countries, with only China, South Korea, and Italy showing different decreases.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What new metric did Medidata introduce to track trial disruptions?",{"text":118,"@type":114},"The release launches a new metric tracking visits per study subject in ongoing studies. Globally and in the US, visits per subject decreased by 17% from Oct 2019 to Mar 2020, with additional region-specific changes described for China.",{"name":120,"@type":111,"acceptedAnswer":121},"How do regulatory responses differ across countries?",{"text":122,"@type":114},"The report states that regulations and guidance differ from country to country. It highlights emergency guidance issued by major authorities and notes contrasting stances on remote source data verification, where the EMA discourages it while some other authorities suggest it may be possible.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},513619,1791477593,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","APRIL 20, 2020  \nCOVID-19 and Clinical Trials: The Medidata Perspective  \nRelease 3.0  \nCopyright 2020 Medidata Solutions, Inc. , a Dassault Systèmes company  \nTable of Contents  \nAPRIL 20, 2020  \nCOVID 19 AND CLINICAL TRIALS: THE MEDIDATA PERSPECTIVE  \n| Introduction | 3 |\n| --- | --- |\n| Regulatory Response | 4 |\n| Impact to Medidata Customers, Patients and Trials | 5 |\n| Medidata Solutions to Assist Sponsors/Partners, Patients and Trials | 5 |\n| Details on Medidata Solutions | 6 |\n\nSummary 11  \nCopyright 2020 Medidata Solutions, Inc. , a Dassault Systèmes company  \nAPRIL 20, 2020  \nCOVID 19 AND CLINICAL TRIALS: THE MEDIDATA PERSPECTIVE  \nIntroduction  \n3  \nAs COVID-19 has spread and, in some Asian countries, begun to recede, we have been monitoring the global impact of the virus on clinical trials. Our first data and insights impact report was released on March 23 with subsequent updates on April 3rd and April 17th. Medidata’s analysis of the change in new patients entering clinical trials for actively recruiting studies demonstrates the growing significance of the pandemic’s impact on cities, regions, and countries with increasingly tighter laws and guidelines restricting movement by anyone outside of the home.1  \nAn update to the April 3 analysis was performed on April 17, 2020 and the results for the first two weeks of April are shown next to the March results (See Exhibit 1), The global data now shows an 75% decrease in the average number of new patients entering trials per study-site YoY for the first two weeks of April compared to the same time frame last year.1 This compares to a 65% decrease we saw in the month of March. The data clearly indicate that the impact of the pandemic on patient enrollment in most countries continues to grow. Only China, South Korea and Italy sawa decrease in impact.  \n Exhibit 1  \n\n|  |  | YoY Difference (%)\u003Cbr>Mar 2020 vs. Mar 2019 | YoY Difference (%) Apr 2020 vs. Apr 2019 |\n| --- | --- | --- | --- |\n| All Countries, All TAs | All | -65.% | -75% |\n| Asia | China | -68% | -39% |\n|  | India | -84% | -96% |\n|  | Japan | -44% | -57% |\n|  | South Korea | -61% | -44% |\n| Europe | France | -68% | -80% |\n|  | Germany | -33% | -76% |\n|  | Italy | -53% | -37% |\n|  | Spain | -68% | -81% |\n|  | United Kingdom | -80% | -98% |\n| North America | United States | -66% | -80% |\n| Therapeutic Area | Cardiovascular | -69% | -95% |\n|  | CNS | -68% | -73% |\n|  | Dermatology | -64% | -90% |\n|  | Endocrine | -81% | -89% |\n|  | ID/Anti-Infectives | -47% | -62% |\n|  | Oncology | -48% | -51% |\n|  | Respiratory | -34% | -78% |\n\n*Monthly data from 2019 normalized to corresponding two weeks in 2020  \n1 Analysis across 4,600 studies and 182,227 study-sites  \nCopyright 2020 Medidata Solutions, Inc. , a Dassault Systèmes company  \nAPRIL 20, 2020  \nCOVID 19 AND CLINICAL TRIALS: THE MEDIDATA PERSPECTIVE  \n4  \nAdditionally, we are launching with this release a new metric tracking visits-per-study-subject in on-going studies (See Exhibit 2) . Both globally and in the US specifically, there has been a 17% decrease in visits per subject between Oct 2019 and March 2020. China has seen a steeper decline with a 30% decrease between Oct 2019 and February 2020 but similar to patient enrollment China saw 22% improvement in visits per subject between February and March 2020. We will continue to update and refine this new metric in upcoming releases.  \nExhibit 2  \nAVERAGE V I S I TS PER SUBJECT  \nOVERALL CHINA UNITED STATES OVERALL ONCOLOGY OTHER  \nUnderstanding what is happening on the ground is critical to define a path forward. We will continue to publish updated analyses twice a month on overall industry trends throughout this pandemic and beyond.  \nRegulatory Response  \nAs of April 16, multiple authorities including the  European Medicines Agency (EMA) , U. S. Food and Drug Administration (FDA), UK  Medicines and Healthcare Products Regulatory Agency (MHRA), Germany ( BfArM), France (ansm), Netherlands (ccmo), Ireland ( HPRA), ","cbCaikkkJAMv1eCa","https://ap.wps.com/l/cbCaikkkJAMv1eCa","pdf",275842,11,"English","# Introduction\n## Regulatory Response\n## Impact to Medidata Customers, Patients and Trials\n## Medidata Solutions to Assist Sponsors/Partners, Patients and Trials\n## Details on Medidata Solutions","[{\"question\":\"How did COVID-19 affect new patient enrollment in clinical trials, according to the report?\",\"answer\":\"Medidata analysis shows a 75% decrease in the average number of new patients entering trials per study-site for the first two weeks of April (YoY), compared with the same period last year. The impact continued to grow in most countries, with only China, South Korea, and Italy showing different decreases.\"},{\"question\":\"What new metric did Medidata introduce to track trial disruptions?\",\"answer\":\"The release launches a new metric tracking visits per study subject in ongoing studies. Globally and in the US, visits per subject decreased by 17% from Oct 2019 to Mar 2020, with additional region-specific changes described for China.\"},{\"question\":\"How do regulatory responses differ across countries?\",\"answer\":\"The report states that regulations and guidance differ from country to country. It highlights emergency guidance issued by major authorities and notes contrasting stances on remote source data verification, where the EMA discourages it while some other authorities suggest it may be possible.\"}]","COVID 19 AND CLINICAL TRIALS - THE MEDIDATA PERSPECTIVE - Release 3.0 | PDF",1791288078,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/df95b668a7a1e7d17fdf13db6b130fd7.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/c577337d1efc663d7b7f7db0f842d767.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/1c56181abc4e774f8773b25d5f826610.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/f29d396566be7f24a7f8ae552dacdf8b.webp",980,1268]